[ad_1]
Rapid Novor Inc. and MAbSilico announced they have partnered to provide the world’s first AI-driven HDX-MS epitope mapping service for antibody development. Seamlessly integrating experimental data from HDX-MS with predictive analysis from AI-driven computational modeling provides researchers with a comprehensive understanding of antibody structure, dynamics, and interactions with unparalleled precision and speed. It will look like this.
“Artificial intelligence promises a turning point in antibody drug discovery and development.” Iain Rogers, Vice President of Sales and Marketing at Rapid Novor, said: “By combining the robustness of HDX-MS with the predictive power of AI-driven computational modeling, we have developed a pipeline that can accelerate antibody discovery and characterization.”
Rapid Novor employs HDX-MS to measure the exchange rate of amide hydrogen atoms to deuterium when exposed to deuterium at various times. By comparing the deuteration levels between the bound and unbound states of the antibody-protein complex, regions protected by antibody binding can be identified. “Leveraging our proteomics expertise” Dr. Dominic Narang, HDX-MS Manager and Senior Scientist at Rapid Novor, explains: “We are able to identify epitopes on target antigens with excellent resolution down to 1-5 amino acids, providing researchers with valuable insight into antibody-antigen interactions.”
MAbSilico’s proprietary algorithm, trained on data from 1 trillion antibodies, uses 3D structural models and docking-based methodologies to predict binding epitopes on target antigens. “Our predictive algorithm is the culmination of 15 years of protein modeling, AI, and machine learning research.” Thomas Bourquard, CSO at MAbSilico, said:. “Our computational modeling accurately predicts epitope binding and is consistently validated in in vitro studies.” In addition, the company’s AI platform can also perform epitope binning to screen hundreds of antibody sequences for functionally related epitopes to assess their development potential.
The integration of AI-guided epitope mapping not only informs the design of in vitro experiments to target the most relevant regions of the antigen, but also aids in identifying binding sites for antibody-antigen interactions. We guarantee the highest quality, reliability and resolution.
This AI-integrated approach enables rapid screening of antibodies from a broad pool of candidates. This accelerates the pace of antibody discovery and development, ultimately leading to the development of novel therapeutics with improved efficacy.
Zak Omahdi, Scientific Business Developer, MAbSilico
[ad_2]
Source link
